Grade 3 and 4 toxicities experienced on arm BV of ANHL12P1 (399 cycles)
| . | Grade 3 . | Grade 4 . | ||
|---|---|---|---|---|
| Adverse event . | No. of cycles . | % . | No. of cycles . | % . |
| Hematological | ||||
| Anemia | 55 | 13.8 | 3 | 0.8 |
| Neutropenia | 20 | 5.0 | 76 | 19.0 |
| Thrombocytopenia | 22 | 5.5 | 34 | 8.5 |
| Febrile neutropenia | 52 | 13.0 | 2 | 0.5 |
| Gastrointestinal | ||||
| Mucositis oral | 21 | 5.3 | 1 | 0.3 |
| Anaphylaxis | 1 | 0.3 | ||
| Infections | ||||
| Appendicitis | 1 | 0.3 | ||
| Catheter-related infection | 2 | 0.5 | ||
| Infections and infestations; other, specify | 7 | 1.8 | 1 | 0.3 |
| Lung infection | 3 | 0.8 | ||
| Sepsis | 1 | 0.3 | ||
| Skin infection | 1 | 0.3 | ||
| Urinary tract infection | 2 | 0.5 | ||
| Laboratory | ||||
| Alanine aminotransferase increased | 15 | 3.8 | 4 | 1.0 |
| Aspartate aminotransferase increased | 8 | 2.0 | 1 | 0.3 |
| Hypokalemia | 13 | 3.3 | 1 | 0.3 |
| Vascular | ||||
| Thromboembolic event | 3 | 0.8 | ||
| . | Grade 3 . | Grade 4 . | ||
|---|---|---|---|---|
| Adverse event . | No. of cycles . | % . | No. of cycles . | % . |
| Hematological | ||||
| Anemia | 55 | 13.8 | 3 | 0.8 |
| Neutropenia | 20 | 5.0 | 76 | 19.0 |
| Thrombocytopenia | 22 | 5.5 | 34 | 8.5 |
| Febrile neutropenia | 52 | 13.0 | 2 | 0.5 |
| Gastrointestinal | ||||
| Mucositis oral | 21 | 5.3 | 1 | 0.3 |
| Anaphylaxis | 1 | 0.3 | ||
| Infections | ||||
| Appendicitis | 1 | 0.3 | ||
| Catheter-related infection | 2 | 0.5 | ||
| Infections and infestations; other, specify | 7 | 1.8 | 1 | 0.3 |
| Lung infection | 3 | 0.8 | ||
| Sepsis | 1 | 0.3 | ||
| Skin infection | 1 | 0.3 | ||
| Urinary tract infection | 2 | 0.5 | ||
| Laboratory | ||||
| Alanine aminotransferase increased | 15 | 3.8 | 4 | 1.0 |
| Aspartate aminotransferase increased | 8 | 2.0 | 1 | 0.3 |
| Hypokalemia | 13 | 3.3 | 1 | 0.3 |
| Vascular | ||||
| Thromboembolic event | 3 | 0.8 | ||
CTCAE, Common Terminology Criteria for Adverse Events version 4.0.